Cel Sci (CVM) Current Assets (2010 - 2026)
Cel Sci (CVM) posted Current Assets of $2.9 million for Q1 2026, down 58.84% sequentially from $7.0 million in Q4 2025, and down 4.27% YoY from $3.0 million in Q1 2025.
Cel Sci (CVM) Current Assets (2010 - 2026) Analysis & Trends
Cel Sci has reported Current Assets for 16 years, with the latest figure at $2.9 million in Q1 2026.
- Quarterly Current Assets fell 4.27% year-over-year to $2.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.9 million (down 4.27% YoY) and the FY2025 annual result came in at $11.6 million, up 91.49% from the prior year.
- Current Assets slipped to $2.9 million in Q1 2026 per CVM's latest filing, from $7.0 million in the prior quarter.
- Over five years, Current Assets peaked at $37.3 million in Q1 2022 and troughed at $2.6 million in Q2 2025.
- A 5-year average of $11.7 million and a median of $7.0 million in 2025 frame the typical range for Current Assets.
- The sharpest annual moves came in 2023 and 2025: Current Assets tumbled 75.02% in 2023, then surged 91.49% in 2025.
- Over 5 years, Current Assets stood at $20.4 million in 2022, then plunged by 69.84% to $6.2 million in 2023, then fell by 4.82% to $5.9 million in 2024, then increased by 20.01% to $7.0 million in 2025, then plunged by 58.84% to $2.9 million in 2026.
- According to Business Quant data, Current Assets over the past three periods registered $2.9 million, $7.0 million, and $11.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.62 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 18.80 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.63 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 1.76 Bn |
| 10 | Cel Sci | 2.12 Mn | -4.42 Mn | - | 7.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.89 Mn |
| Dec 31, 2025 | 7.03 Mn |
| Sep 30, 2025 | 11.60 Mn |
| Jun 30, 2025 | 2.62 Mn |
| Mar 31, 2025 | 3.02 Mn |
| Dec 31, 2024 | 5.86 Mn |
| Sep 30, 2024 | 6.06 Mn |
| Jun 30, 2024 | 3.54 Mn |
| Mar 31, 2024 | 8.51 Mn |
| Dec 31, 2023 | 6.15 Mn |
| Sep 30, 2023 | 6.92 Mn |
| Jun 30, 2023 | 7.73 Mn |
| Mar 31, 2023 | 12.57 Mn |
| Dec 31, 2022 | 20.40 Mn |
| Sep 30, 2022 | 25.44 Mn |
| Jun 30, 2022 | 30.96 Mn |
| Mar 31, 2022 | 37.28 Mn |
| Dec 31, 2021 | 41.87 Mn |
| Sep 30, 2021 | 45.27 Mn |
| Jun 30, 2021 | 49.73 Mn |